Published in Blood on January 25, 2005
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res (2007) 1.56
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy (2010) 1.50
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood (2015) 1.47
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood (2010) 1.20
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica (2011) 1.00
A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun (2010) 0.97
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther (2011) 0.95
Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol (2012) 0.91
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant (2015) 0.89
Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. J Immunol (2009) 0.89
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother (2012) 0.88
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Cancer-testis antigens: the current status on antigen regulation and potential clinical use. Am J Blood Res (2012) 0.87
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. Br J Haematol (2012) 0.87
Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies. Oncoimmunology (2013) 0.84
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol (2012) 0.84
Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol (2009) 0.83
Novel immunotherapies. Cancer J (2009) 0.82
Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci (2016) 0.82
CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica (2010) 0.81
Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med (2012) 0.80
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother (2014) 0.79
Prognostic and diagnostic value of spontaneous tumor-related antibodies. Clin Dev Immunol (2010) 0.78
Dendritic cell cancer vaccines: from the bench to the bedside. Rambam Maimonides Med J (2014) 0.77
Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget (2016) 0.76
Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer (2014) 0.76
Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy (2013) 0.76
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. Haematologica (2012) 0.76
Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biol Blood Marrow Transplant (2015) 0.76
Immunogenic targets for specific immunotherapy in multiple myeloma. Clin Dev Immunol (2012) 0.75
Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens. Iran J Cancer Prev (2015) 0.75
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia. PLoS One (2015) 0.75
Melanoma: tumor microenvironment and new treatments. An Bras Dermatol (2017) 0.75
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol (1994) 8.16
Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med (2003) 7.35
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
New paths in human cancer serology. J Exp Med (1998) 3.12
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A (1999) 2.60
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood (2002) 2.48
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood (2002) 2.38
Treatment of multiple myeloma. Blood (2003) 2.34
CD4 T cells and their role in antitumor immune responses. J Exp Med (1999) 2.27
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer (1999) 2.26
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A (2001) 1.96
Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer (1999) 1.91
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood (2002) 1.87
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol (2000) 1.76
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene (2002) 1.53
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res (2000) 1.47
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res (2004) 1.44
Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol (1995) 1.39
Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood (1999) 1.37
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest (2002) 1.36
Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J Immunother (2001) 1.35
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun (2003) 1.32
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun (2003) 1.19
Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol (2001) 1.18
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol (2003) 1.18
Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood (2001) 1.16
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol (1997) 1.06
Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol (2002) 1.05
Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood (2002) 1.04
NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer (2000) 1.01
Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun (2003) 1.00
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood (1999) 0.99
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun (2003) 0.99
Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab (2003) 0.92
Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck (2003) 0.91
SEREX analysis of gastric cancer antigens. Cancer Chemother Pharmacol (2000) 0.85
Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant (1997) 0.85
Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology (2003) 0.83
Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH. Int J Hematol (2002) 0.82
Tumour-associated antigens in multiple myeloma. Br J Haematol (2003) 0.82
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
The molecular classification of multiple myeloma. Blood (2006) 8.77
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood (2002) 2.48
Treatment of multiple myeloma. Blood (2003) 2.34
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer (2004) 2.26
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol (2004) 2.16
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. Nat Immunol (2011) 1.96
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood (2008) 1.93
Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood (2003) 1.87
Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol (2013) 1.84
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J (2003) 1.81
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A (2007) 1.80
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood (2008) 1.76
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood (2005) 1.71
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell (2013) 1.67
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood (2002) 1.65
Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol (2006) 1.64
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell (2006) 1.58
Wnts induce migration and invasion of myeloma plasma cells. Blood (2005) 1.58
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood (2012) 1.58
Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica (2006) 1.58
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56
Rapid identification of a disease allele in mouse through whole genome sequencing and bulk segregation analysis. Genetics (2010) 1.56
Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2010) 1.55
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood (2007) 1.55
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol (2002) 1.54
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol (2002) 1.54
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res (2007) 1.53
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy (2010) 1.50
B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol (2011) 1.49
Religious struggle and religious comfort in response to illness: health outcomes among stem cell transplant patients. J Behav Med (2005) 1.45
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell (2007) 1.45
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol (2008) 1.44
NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw (2009) 1.44
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol (2014) 1.43
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther (2009) 1.40
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget (2010) 1.40
Tandem transplants in the treatment of multiple myeloma. Pro. Clin Adv Hematol Oncol (2004) 1.39
Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol (2009) 1.34
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood (2007) 1.33
Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer (2005) 1.32
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res (2008) 1.29
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood (2007) 1.26
Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol (2002) 1.26
Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol (2005) 1.24
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood (2002) 1.23
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood (2006) 1.21
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther (2013) 1.21
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood (2002) 1.20
High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica (2007) 1.18
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol (2003) 1.18
Pancreatitis in patients with primary hyperparathyroidism. Indian J Gastroenterol (2004) 1.17
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol (2007) 1.16
Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer (2005) 1.16